Compare Amgen, Inc. (AMGN) vs FTAI Aviation Ltd (FTAI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs FTAI Aviation Ltd — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while FTAI Aviation Ltd trades at $224.9 (market cap $23.33B). The key difference: Amgen, Inc. is far larger — about 8.4× FTAI Aviation Ltd's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | FTAI | |
|---|---|---|
Market Cap | $196.12B | $23.33B |
Sector | Health | Industrials |
52-Week High | $388.16 | $310.04 |
52-Week Low | $271.18 | $109.92 |
Enterprise Value | $241.41B | $26.37B |
Dividend Yield | 2.77% | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
FTAI Aviation trades at $227.35, down 0.29% on the day, with a bearish technical signal despite strong analyst consensus. The company reported Q1 2026 EPS of $1.29, missing expectations of $1.50, but maintains robust revenue growth and a net income margin of 18.92%. Recent strategic collaborations and a dividend increase to $0.45 highlight management's confidence in long-term prospects, particularly in aerospace services and data center power solutions.
Outlook remains positive driven by aerospace demand and innovation in power solutions, though risks include earnings misses and high valuation multiples. With 100% buy ratings from analysts and institutional support, the stock offers growth potential but requires monitoring of execution against forecasts and competitive pressures in evolving markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →
